Key Highlights

  • Hutchmed shares closed up 17% at $14.11.
  • The company entered an exclusive ex-China development and commercialization license with GSK for HMPL-A830.
  • Terms include $110 million upfront and up to $1.3 billion in total milestones plus royalties.
  • Hutchmed will lead global Phase 1 development, expected to start in the second half of 2026, before GSK assumes later-stage development.

Hutchmed (China) Limited (NASDAQ: HCM) shares closed up 17% at $14.11 after entering an exclusive ex-China development and commercialization license with GSK for HMPL-A830, receiving $110 million upfront and up to $1.3 billion in total milestones plus royalties.

What Happened

Hutchmed will lead global Phase 1 development, expected to start in the second half of 2026, before GSK assumes later-stage development and commercialization outside Greater China.

Market Reaction

Shares rose sharply as investors responded to the scale of the upfront payment and total potential deal value, along with the validation of HMPL-A830 from a major pharmaceutical partner.

Outlook

The start of global Phase 1 development, expected in the second half of 2026, represents the next disclosed milestone for HMPL-A830 under the new GSK partnership.